6 November 2020This updated Medicines Q&A is a quick reference summary to different types of enteral feeding tubes, in relation to medication issues. Not all enteral feeding…
5 November 2020Monitor infant for gastro-intestinal disturbances and oral candida infection, especially if used for prolonged periods or in high doses, although these effects are unlikely to…
1 October 2020The evidence for an interaction between methotrexate and penicillins is limited to case reports and animal studies. So far, there is no conclusive evidence that…
TaliciaHelicobacter pylori bacterial infection - first-line
RedHill Biopharma Ltd
RedHill Biopharma Ltd
Development and Regulatory status
May 21At present the company appears to have no plans to launch in the UK 
Nov 19Approved in the US 
May 19RedHill Biopharma has submitted a New Drug Application to US FDA for the approval of amoxicillin/omeprazole/rifabutin for the treatment of H. pylori infections .
Nov 14FDA Grants Qualified Infectious Disease Product (QIDP) fast-track designation for RHB-105 in H.Pylori .
Antibiotics + PPI combination product for H Pylori
The prevalence in 2008 was 30-40% in the UK adult population with pockets of higher prevalence associated with deprivation. The prevalence has in fact decreased considerably over the period of a decade. 
Helicobacter pylori bacterial infection - first-line
Trial or other data
May 20PIII ERADICATE Hp2 study (NCT03198507, n=455) is published; it found a superior eradication rate with a combination of rifabutin, amoxicillin and omeprazole vs amoxicillin and omeprazole (83.8% vs 57.7%, p<0.001). Diarrhoea was more common with the rifabutin combination regimen (10.1% vs 7.9%) .
Dec 18Broader spectrum of activity than current regimens as cited by manufacturer .
Jun 15Top-line results from the RHB-105 PIII study was designed to evaluate the safety and efficacy of RHB-105 as a first-line treatment for confirmed H. pylori infection. A total of 118 dyspepsia pts with confirmed H. pylori infection were enrolled and treated in the ERADICATE Hp study. Pts were randomised in a 2:1 ratio to receive either RHB-105 or a placebo for 14 days, and assessed for the eradication of H. pylori infection 28 to 35 days after completion of treatment. RHB-105 demonstrated 89.4% efficacy in eradicating H. pylori infection with RHB-105. The study successfully met its primary endpoint of superiority over historical standard of care efficacy levels of 70% (p<0.001). No serious adverse events or unexpected safety issues were identified. Full results from the RHB-105 PIII study are expected in the third quarter of 2015 .
May 15Dosing with RHB-105 completed in the blinded stage of the ERADICATE Hp PIII study and top-line results are expected in June 2015. The primary endpoint of the study is to show superiority in eradication of H. pylori bacterial infection over historical standard of care efficacy levels of 70% effectiveness. RHB-105 has been granted Qualifying Infectious Disease Product (QIDP) designation by the FDA under the GAIN Act, enabling development to benefit from fast-track status .
Nov 14Top-line data from the ongoing RHB-105 first Phase III study in the US are now expected in the second quarter of 2015 .
Dec 13The first pts have been dosed in the ERADICATE Hp study. PIII data is expected by the third quarter of 2014. 
Nov 13Pt screening process initiated in the ERADICATE Hp study - a PIII clinical study in the U.S. designed to evaluate the safety and efficacy of RHB-105 as a first-line treatment for confirmed H. pylori bacterial infection. 
Topline data from ERADICATE Hp2 study (NCT03198507, n=455) successfully met its primary endpoint of H. pylori eradication (84% vs. 58%, p<0.0001). ERADICATE Hp2 is a 2-arm, randomised, double-blind, active comparator-controlled, confirmatory study in pts with dyspepsia—or indigestion and H. pylori infection. Pts received either 4 capsules TDS for 14 days of either RHB-105 or a combination of amoxicillin and omeprazole. No safety issues were reported in the study and TALICIA® was found to be well tolerated.[7,8]